Lyell Immunopharma Inc (LYEL) - News Archive

SOUTH SAN FRANCISCO, Calif. In a significant leap forward in the treatment of aggressive large B-cell lymphoma, Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical innovator, has announced the initiation of t...

Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy Designation for LYL314 in Overcoming Persistent Large B-Cell Lymphoma South San Francisco, California April 15, 2025 Lyell Immunopharma, Inc. (Nasdaq: L...

Advanced CAR T-cell Therapy Takes Center Stage: Lyell Immunopharma s Promising Clinical Data in Treating B-cell Lymphoma In the rapidly evolving field of immunotherapy, Lyell Immunopharma is making significant strides w...

Lyell Immunopharma Expands CAR T-Cell Therapy Pipeline through Acquisition of ImmPACT BioSOUTH SAN FRANCISCO, Calif. Oct. 31, 2024—In a significant strategic move aimed at enhancing its clinical capabilities and product...

By Author Name, SOUTH SAN FRANCISCO, Calif. — October 24, 2024 — In a pivotal moment for the biotechnology sector, Lyell Immunopharma, Inc. (Nasdaq: LYEL), a leading player in the development of advanced cellular therap...

The pharmaceutical market has been witnessing significant fluctuations, and Lyell Immunopharma Inc (NASDAQ: LYEL) appears to be underperforming with a 15.13% decrease compared to the overall market. This article aims to...

Lyell Immunopharma, a clinical-stage T-cell reprogramming company, has released initial clinical and translational data from its Phase 1 trial of LYL797. This first-generation reprogrammed ROR1 CAR T-cell product candid...